- Home
- NLSP vs SERA Comparison
NLSP vs SERA Comparison
Compare NLSP & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- SERA
- Stock Information
- Founded
- NLSP 2015
- SERA 2008
- Country
- NLSP Switzerland
- SERA United States
- Employees
- NLSP N/A
- SERA N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- SERA Precision Instruments
- Sector
- NLSP Health Care
- SERA Health Care
- Exchange
- NLSP Nasdaq
- SERA Nasdaq
- Market Cap
- NLSP 243.8M
- SERA 258.3M
- IPO Year
- NLSP 2021
- SERA 2021
- Fundamental
- Price
- NLSP $4.90
- SERA $7.21
- Analyst Decision
- NLSP
- SERA
- Analyst Count
- NLSP 0
- SERA 0
- Target Price
- NLSP N/A
- SERA N/A
- AVG Volume (30 Days)
- NLSP 25.9K
- SERA 138.7K
- Earning Date
- NLSP 10-11-2024
- SERA 11-06-2024
- Dividend Yield
- NLSP N/A
- SERA N/A
- EPS Growth
- NLSP N/A
- SERA N/A
- EPS
- NLSP N/A
- SERA N/A
- Revenue
- NLSP N/A
- SERA $107,000.00
- Revenue This Year
- NLSP N/A
- SERA N/A
- Revenue Next Year
- NLSP N/A
- SERA $2,020.00
- P/E Ratio
- NLSP N/A
- SERA N/A
- Revenue Growth
- NLSP N/A
- SERA N/A
- 52 Week Low
- NLSP $4.08
- SERA $1.56
- 52 Week High
- NLSP $40.60
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- NLSP 37.46
- SERA 46.26
- Support Level
- NLSP $4.72
- SERA $6.87
- Resistance Level
- NLSP $5.50
- SERA $8.19
- Average True Range (ATR)
- NLSP 0.65
- SERA 0.50
- MACD
- NLSP 0.02
- SERA -0.06
- Stochastic Oscillator
- NLSP 28.47
- SERA 25.00
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.